Birgit Schultes, Ph.D.

Birgit Schultes, Ph.D.

Executive Vice President, Chief Scientific OfficeratIntellia Therapeutics· In the 2025 proxy

Pay in FY2025Intellia Therapeutics stock -22.9% the same year

Birgit Schultes, Ph.D. was paid $1.7M in FY2025 (Dec). Intellia Therapeutics stock fell 22.9% that year.

Pay$100 in the stock at the end of FY24 → $77
Pay is from the Summary Compensation Table of each Intellia Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Intellia TherapeuticsPublic company · 1 yr
    • Executive Vice President, Chief Scientific Officer2025 – Present · 1 yrStock in role +11%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?